Stay updated on Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page presents details for a phase II trial of nivolumab and brentuximab vedotin in older or chemotherapy-ineligible patients with untreated Hodgkin lymphoma. It also includes participant criteria, study locations, outcome measures, and posted results.
    Difference
    59%
    Check dated 2026-11-08T04:50:25.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The clinical trial record for nivolumab and brentuximab vedotin is no longer displayed; the page instead shows a 403 Forbidden message.
    Difference
    19%
    Check dated 2026-11-01T02:14:38.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A sitewide notice announces that NIH is using “Super Intelligence” in place of “Artificial Intelligence” during a transition. It appears above the study page, which displays a 403 error.
    Difference
    1%
    Check dated 2026-10-25T02:12:31.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now shows revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-18T02:00:08.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The site revision label in the footer changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T02:55:56.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study content with a 403 message and site chrome. This indicates the study record is not accessible at the moment.
    Difference
    19%
    Check dated 2026-09-20T01:21:55.000Z thumbnail image

Stay in the know with updates to Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Brentuximab Vedotin in Older Hodgkin Lymphoma Clinical Trial page.